acquired hemophilia A

Summary

acquired hemophilia A (MONDO:0035735) is a disease and 12 clinical trials. Top therapeutic interventions include cyclophosphamide anhydrous, susoctocog alfa, and emicizumab. A subtype of acquired hemophilia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Europe) [Orphanet-validated]
• Clinical trials: 12

Clinical features

Epidemiology

Prevalence records

8 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.1505	Europe	Validated
Annual incidence	1-9 / 100 000	0.141	United Kingdom	Validated
Annual incidence	<1 / 1 000 000	0.0829	Spain	Validated
Annual incidence	1-9 / 1 000 000	0.6	Germany	Validated
Annual incidence	1-9 / 1 000 000	0.12	Australia	Validated
Annual incidence	<1 / 1 000 000	0.097	Japan	Validated
Annual incidence	1-9 / 1 000 000	0.45	Switzerland	Validated
Point prevalence	1-9 / 1 000 000	0.3063	Spain	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	acquired hemophilia A
Mondo ID	MONDO:0035735
MeSH	C536392
Orphanet	599480
NCIT	C35345
UMLS	C0272325
MedGen	124426
GARD	0006405
Is cancer (heuristic)	no

Also known as: AHA

Disease family

This is a subtype of acquired hemophilia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › hemorrhagic disease › acquired hemophilia › acquired hemophilia A

Related subtypes (2): acquired hemophilia B, acquired factor XI deficiency

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 12.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE2/PHASE3	2
PHASE2	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03384277	PHASE4	COMPLETED	Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab
NCT01178294	PHASE2/PHASE3	COMPLETED	Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
NCT04580407	PHASE2/PHASE3	COMPLETED	Study of TAK-672 in Participants With Acquired Hemophilia A
NCT05345197	PHASE2	ACTIVE_NOT_RECRUITING	Emicizumab in Patients With Acquired Hemophilia A
NCT03700229	PHASE2	UNKNOWN	Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A
NCT06461533	Not specified	RECRUITING	A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A
NCT06550882	Not specified	RECRUITING	A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea
NCT01090349	Not specified	COMPLETED	Clinical Evaluation Of Remote Monitoring With Direct Alerts To Reduce Time From Event To Clinical Decision
NCT01968655	Not specified	NO_LONGER_AVAILABLE	Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
NCT02004873	Not specified	COMPLETED	Micra Transcatheter Pacing Study
NCT02610127	Not specified	COMPLETED	Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
NCT03199794	Not specified	COMPLETED	Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPHOSPHAMIDE ANHYDROUS	4	3
SUSOCTOCOG ALFA	4	3
EMICIZUMAB	4	1
RITUXIMAB	4	1